# US 2021/0332014 A1 · Cabozantinib malate crystal form, preparation method and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332014 A1
- Document ID: US20210332014A1
- Status: Published application
- Kind: A1
- Application number: 17/278,138
- Filed: 2019-09-20
- Published: 2021-10-28
- Earliest claimed: 2018-09-20
- Assignees: Crystal Pharmaceutical (Suzhou) Co., Ltd.
- Applicants: Crystal Pharmaceutical (Suzhou) Co., Ltd.
- Inventors: Minhua Chen; Yanfeng Zhang; Xiaoting Zhai; Jing Zhang; Qun Zhang
- Web page: https://patentgrep.com/patent/US20210332014A1

## CPC

- C07D 215/233: only one oxygen atom which is attached in position 4
- C07D 215/22: attached in position 2 or 4
- A61K 31/47: Quinolines; Isoquinolines
- A61P 35/00: Antineoplastic agents
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention relates to novel cabozantinib malate crystalline forms, preparation methods for the cabozantinib malate, a pharmaceutical composition comprising the novel cabozantinib malate crystalline forms, and use of the novel cabozantinib malate crystalline forms in the preparation of MET, VEGFR1/2/3, ROS1, RET, AXL, NTRK, and KIT inhibitors and pharmaceutical preparations for treating cancers such as thyroid cancer, lung cancer, kidney cancer and liver cancer. The cabozantinib malate crystalline forms provided by the present invention has one or more improved properties compared with the prior art, and the preparation method for the cabozantinib malate provided by the present disclosure has a lower cost and better quality of the obtained product compared with the prior art, having important value for future optimization and development of this drug.

## Claims

### Claim 1

A process for preparing crystalline form M2 of Compound I, wherein the process comprises: dissolving Compound I solid or a mixed solid of cabozantinib and (S)-malic acid in a solvent and then adding an anti-solvent to precipitate a solid, then drying the obtained solid under a condition of above 30% relative humidity (RH) to obtain crystalline form M2, wherein said solvent is an organic acid or a mixture of organic acid and aromatic hydrocarbon; said anti-solvent is an aromatic hydrocarbon or an ester or an alcohol or a ketone or a mixture of an aromatic hydrocarbon and an ester or a mixture of an aromatic hydrocarbon and a ketone; wherein the X-ray powder diffraction pattern of said crystalline form M2 comprises characteristic peaks at 2 theta values of 8.6°±0.2 °, 12.6 °±0.2°, 20.2°±0.2°, 23.4°±0.2°, and 26.1°±0.2.

### Claim 2 (depends on 1)

The process for preparing crystalline form M2 of Compound I according to claim 1, wherein said organic acid is acetic acid, said aromatic hydrocarbon is toluene, said ester is ethyl acetate or isopropyl acetate, said ketone is methyl isobutyl ketone, and said alcohol isopropanol or n-propanol.

### Claim 3 (depends on 1)

The process for preparing crystalline form M2 of Compound I according to claim 1, wherein the temperature of the solvent system is below 15° C. when adding an anti-solvent.

### Claim 4 (depends on 3)

The process for preparing crystalline form M2 of Compound I according to claim 3, wherein the temperature of the solvent system is −5° C. to 10° C. when adding an anti-solvent.

### Claim 5 (depends on 1)

The process for preparing crystalline form M2 of Compound I according to claim 1, wherein seed crystals of crystalline form M2 can be added before adding the anti-solvent and the amount of the seed crystals are 1 wt % to 10 wt %.

### Claim 6 (depends on 1)

The process for preparing crystalline form M2 of Compound I according to claim 1, wherein the volume ratio of said solvent and said anti-solvent is 1:1 to 1:10.

### Claim 7 (depends on 6)

The process for preparing crystalline form M2 of Compound I according to claim 6, wherein the volume ratio of said solvent and said anti-solvent is 2:5.

### Claim 8

A crystalline form CSI of Compound I, wherein the X-ray powder diffraction pattern comprises characteristic peaks at 2 theta values of 8.5°±0.2°, 12.7°±0.2° and 13.9°±0.2° using CuKα radiation.

### Claim 9 (depends on 8)

The crystalline form CSI of Compound I according to claim 8, wherein the X-ray powder diffraction pattern comprises one or two or three characteristic peaks at 2 theta values of 12.1°±0.2°, 17.9°±0.2° and 19.9°±0.2° using CuKα radiation.

### Claim 10 (depends on 8)

The crystalline form CSI of Compound I according to claim 8, wherein the X-ray powder diffraction pattern comprises one or two or three characteristic peaks at 2 theta values of 14.9°±0.2°, 16.7°±0.2° and 25.5°±0.2° using CuKα radiation.

### Claim 11 (depends on 8)

A process for preparing of crystalline form CSI of Compound I according to claim 8, wherein the process comprising:
Method 1: dissolving Compound I in acetic acid or a solvent mixture of acetic acid and an aromatic hydrocarbon, then rapidly evaporating at 50-80° C.; or
Method 2: dissolving the Compound I in acetic acid, a mixture of acetic acid and an aromatic, a mixture of acetic acid and an alkane, or a mixture of acetic acid and water; then adding an aromatic hydrocarbon, an alkane, an ester or a ketone into the solution with stiffing to obtain crystalline form CSI.

### Claim 12 (depends on 11)

The process for preparing of crystalline form CSI of Compound I according to claim 11, wherein said aromatic hydrocarbon in Method 1 is toluene, the volume ratio of said acetic acid and toluene is 2:1-1:3.

### Claim 13 (depends on 12)

The process for preparing of crystalline form CSI of Compound I according to claim 12, wherein the volume ratio of said acetic acid and toluene is 1:1.

### Claim 14 (depends on 11)

The process for preparing of crystalline form CSI of Compound I according to claim 11, wherein the volume ratio of said acetic acid and aromatic, acetic acid and alkane, or acetic acid and water in Method 2 is 2:1-1:3.

### Claim 15 (depends on 11)

The process for preparing of crystalline form CSI of Compound I according to claim 11, wherein in Method 2, said aromatic hydrocarbon is toluene, said alkane is n-heptane, said ester is isopropyl acetate, and said ketone is methyl isobutyl ketone.

### Claim 16 (depends on 11)

The process for preparing of crystalline form CSI of Compound I according to claim 11, wherein said stiffing in Method 2 is at 0-5° C.

### Claim 17

A crystalline form CSIII of Compound I of Compound I, wherein the X-ray powder diffraction pattern comprises characteristic peaks at 2 theta values of 8.5°±0.2°, 21.3°±0.2°, and 23.0°±0.2° using CuKα radiation.

### Claim 18 (depends on 17)

The crystalline form CSIII of Compound I according to claim 17, wherein the X-ray powder diffraction pattern comprises one or two or three characteristic peaks at 2 theta values of 14.4°±0.2°, 17.8°±0.2°, and 12.6°±0.2° using CuKα radiation.

### Claim 19 (depends on 17)

The crystalline form CSIII of Compound I according to claim 17, wherein the X-ray powder diffraction pattern comprises one or two or three characteristic peaks at 2 theta values of 20.5°±0.2°, 24.0°±0.2°, and 16.4°±0.2° using CuKα radiation.

### Claim 20 (depends on 17)

A process for preparing crystalline form CSIII of Compound I according to claim 17, wherein the process comprising:
Method 1: dissolving Compound I in an acid, a solvent mixture of an acid and an aromatic hydrocarbon, a solvent mixture of an acid and an alkane, or a solvent mixture of an acid and water, adding an aromatic hydrocarbon, an alkane, an ester or a ketone into the solution with stiffing to obtain a precipitate, then slurring the obtained solid in a solvent mixture of an aromatic hydrocarbon and water, separation again to obtain the crystalline form CSIII; or
Method 2:
step 1: dissolving the Compound I in an acid, stiffing and heating until the solid is completely dissolved, then naturally cooling the system to room temperature and filtering;
step 2: adding an aromatic hydrocarbon in the clear solution dropwise, then transferring the mixture to an environment at 0-10° C. and continuing stiffing, filtering the mixture to separate the solid, and drying;
step 3: heating the solid to 50-100° C. under nitrogen purging, and then cooling to 30° C. to obtain Form CSIII.

### Claim 21 (depends on 20)

The process for preparing crystalline Form CSIII of Compound I according to claim 20, wherein the volume ratio of said acid and aromatic hydrocarbon, acid and alkane, or acid and water in Method 1 is 2:1-1:3.

### Claim 22 (depends on 20)

The process for preparing crystalline form CSIII of Compound I according to claim 20, wherein in Method 1, said acid is acetic acid, said aromatic hydrocarbon is toluene, said alkane is n-heptane, said ester is isopropyl acetate, and said ketone is methyl isobutyl ketone.

### Claim 23 (depends on 20)

The process for preparing crystalline form CSIII of Compound I according to claim 20, wherein in Method 2, said acid is acetic acid, said aromatic hydrocarbon is toluene.

### Claim 24 (depends on 20)

The process for preparing crystalline form CSIII of Compound I according to claim 20, wherein said stiffing in step 1 of Method 2 is performed at 80° C.; said stiffing in step 2 is performed at 5° C., the time of said stiffing in step 2 is 10-20 hours, and said heating in step 3 is up to 100° C.

### Claim 25 (depends on 8)

A pharmaceutical composition, wherein the pharmaceutical composition comprises a therapeutically effective amount of crystalline form CSI of Compound I according to claim 8, and a pharmaceutically acceptable carrier, a dilution agent or an excipient.

### Claim 26 (depends on 8)

A method for treating a disease associated with inhibition of MET, VEGFR1/2/3, ROS1, RET, AXL, NTRK, or KIT, comprising administering to a subject in need thereof a therapeutically effective amount of crystalline form CSI of Compound I according to claim 8.

### Claim 27 (depends on 8)

A method for treating thyroid cancer, lung cancer, gastric cancer, or liver cancer, comprising administering to a subject in need thereof a therapeutically effective amount of crystalline form CSI of Compound I according to claim 8.